-
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases
-
With 300,000 square feet (27,870 square meters), it is the largest dedicated cell-and-gene-therapy manufacturing facility in the world
-
Facility to reach 200 full-time staff by end of 2018 and continue to recruit high-value positions as market demand increases
Cellect Announces a Major Milestone for Enabling Stem Cells Production
Highlights
- Successfully completes POC testing for first ever scalable production of ApoTainer™
- Cellect’s ApoTainer™ built to replace complex laboratory procedures for stem cell extraction at a fraction of the time and cost
- Dr. Shai Yarkoni, Cellect CEO commented: “We believe that the expected demand for stem cells as raw material for regenerative medicine will explode over the next five years. Our ApoTainer™ is intended to ensure this demand is met with a cost-effective quality manufacturing of stem cells.”
- The ApoTainer™ is covered by a portfolio of IP including a patent application for apoptotic selection of stem cells using FasL-coated magnetic beads
Exosome Manufacturing: $2.18M Grant Awarded to VivaZome Therapeutics
$2.18m grant awarded to VivaZome Therapeutics for Exosome Therapy; Grant awarded in collaboration with La Trobe University and SeerPharma
18 December 2017, Geelong – Melbourne, Australia: Australian biotech company VivaZome Therapeutics is pleased to announce that it has been awarded an Australian Government CRC-P grant of $2.18m in support of the project “Enabling Exosome Therapy: Developing an Advanced Manufacturing Process”, with the funds provided under the Advanced Manufacturing Scheme.
The Hon Craig Laundy MP (Assistant Minister for Industry, Innovation and Science) oversees the Cooperative Research Centre Projects (CRC-P) Grants Scheme which supports the development of innovative Australian companies and sectors.
Joining VivaZome in the CRC-P are La Trobe University and SeerPharma Pty Ltd, each of which bring high-level scientific and operational skills to the 3 –year project. VivaZome will also engage with the CSIRO to provide expertise in industrial–scale manufacturing. [Read more…]
GenCure Opens BioManufacturing Center for cGMP Production of Human MSCs
Biologics development and manufacturing organization supports transfer of laboratory research from preclinical evaluation through clinical trials and commercialization
WuXi Biologics Initiated cGMP Manufacturing in the World’s Largest Biologics Manufacturing Facility Using Only Single-Use Bioreactors
December 6, 2017, WUXI, China, Dec. 6, 2017 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, announced that its cGMP biologics manufacturing facility in Wuxi city with 30,000 L bioreactor capacity entered into full operations. This marks a significant milestone for WuXi Biologics as well as the biologics industry in China.